NICE rejects Tyverb as too costly; German Merck wants to make a deal;

> The U.K.'s cost-benefit experts say GlaxoSmithKline's cancer drug Tyverb (Tykerb) is too expensive for the benefits it provides; it runs nearly $40,000 per year and costs some $160,000 to administer. Report

> Merck KGaA is "intensively" considering acquisitions to add to either its pharmaceuticals or its chemicals division, Chief Executive Karl-Ludwig Kley told Handelsblatt in an interview. Report

> Hungary's Richter Gedeon announced that its deal to buy Poland's Polpharma is unlikely to be consummated. Report

> Tibotec Pharmaceuticals said Europe's Committee for Human Medicinal Products (CHMP) recommended conditional approval of its HIV medication Intelence (etravirine) in the European Union. Report

> Deutsche Bank downgraded AstraZeneca to hold from buy, saying that the recent victories preserving Nexium and Seroquel patent protection boosted the stock price in line with its fair value. Report

> Angiotech Pharmaceuticals is packaging its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. Report

> Probio Nutraceuticals has agreed to buy Gelkaps, which manufactures pharmaceutical and nutraceutical grade soft gelatin capsules. Report

> A shortage of new money is likely to drive more and more life sciences companies into mergers and acquisitions, say some of the industry's top analysts. Report

> A FDA advisory panel has voted 14-2 to recommend that the developers of diabetes drugs specifically demonstrate that their experimental therapies don't increase cardiovascular risks. Diabetes report

> ARYx Therapeutics says that Procter & Gamble surprisingly dropped out of a pact to develop an experimental therapy for chronic constipation and dyspepsia. ARYx report

> The Financial Times has consulted the experts in drug discovery and settled on three new technologies that promise to transform patient care in years to come. Report

Emerging Drug Developer: Gemin X Pharmaceuticals

And finally ... Experts are pushing the FDA to boost Vitamin D requirements, citing a dizzying array of possible health benefits. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.